OVERVIEW

Immediately upon completion of the [**REDACTED**] and the [**REDACTED**] and without taking into account any Shares which may be issued pursuant to the exercise of the [**REDACTED**] or any options which may be granted under the [**REDACTED**] Share Scheme, Tri-Link Ventures and Creative Summit will, in aggregate, directly hold approximately [**REDACTED**] of the issued share capital of our Company. Tri-Link Ventures is a company wholly owned by Mr. Wang. Creative Summit is wholly owned by Tri-Link Ventures, which in turn is wholly owned by Mr. Wang, the trustee of the RSU Scheme Trust who holds shares in Creative Summit through Tri-Link Ventures for the purpose of the RSU Scheme. The RSU Scheme Trust is a fixed trust established by our Company as the settlor and is intended for the benefit of eligible persons entitled to receive a grant of the RSUs in accordance with the terms of the RSU Scheme. Accordingly, Mr. Wang, Tri-Link Ventures and Creative Summit constitute a group of our Controlling Shareholders under the Listing Rules.

Tri-Link Ventures is an investment holding company. Creative Summit is the holding company for the administration of the RSU Scheme and holds the Shares on trust for the eligible persons entitled to receive a grant of the RSUs in accordance with the terms of the RSU Scheme. Mr. Wang founded Henan Genuine in September 2012 and served as the director and legal representative of Henan Genuine from September 2012 to September 2018 and was responsible for decision-making and formulation of development strategies of our Group prior to the joining of Dr. Du in January 2019. Apart from his interests in our Group, Mr. Wang has invested in other businesses, details of which are set out in "—Delineation of Business—Other business invested by Mr. Wang" in this section below. He served as a member of the National People's Congress of PRC from 2013 to 2023. He has also been serving as a vice president and a member of the executive committee of the Henan Federation of Industry and Commerce (河南省工商業聯合會) since August 2022, the president of Henan Yingcheng Chamber of Commerce (河南省鷹城商會) since January 2024 and the honorary president of the National Revolutionary Henan Provincial Entrepreneurs Association (民革河南省企業家聯誼會) since February 2024. Given (i) Mr. Wang's plan to focus on his other businesses and public and organizational affairs; and (ii) the past successful achievement of our Group in R&D of drugs and business operations led by our management team, Mr. Wang entrusted the overall management and business operations of our Group to our core management team led by Dr. Du, the chairman of our Board, our executive Director, chief executive officer and chief scientific officer. Dr. Du is also a substantial Shareholder of our Company.

DELINEATION OF BUSINESS

Business of our Group

Our Group is dedicated to the development, manufacturing and commercialization of innovative drugs for the treatment of viral infections, oncological and cardio-cerebrovascular diseases.

Other business invested by Mr. Wang

Apart from our business, Mr. Wang is involved in other businesses which mainly include real estate development, property leasing and tar deep processing ("**Mr. Wang's Other Businesses**") through companies owned and/or controlled by him. Given the difference between the business of our Group and Mr. Wang's Other Businesses, there is a clear delineation between our business and Mr. Wang's Other Businesses. Our Directors are therefore of the view that there is no competition between our business and Mr. Wang's Other Businesses.

Other business invested by Dr. Du

Apart from our business, Dr. Du is beneficially interested in 78% of equity interest in Meitaibao, a company which was principally engaged in drug R&D, through Mr. Du Jianping, a nephew of Dr. Du who holds such equity interest as nominee for and on behalf of Dr. Du. Meitaibao transferred all its intellectual property rights in relation to our business to our Group in 2019 and had not carried out any business which competes or is likely to compete with our business as of the Latest Practicable Date. See "Business —Our Technology Transfer Arrangements and Collaborations—Meitaibao Technology Transfer Agreement" for the details of the transfer arrangement.

To ensure that competition will not exist in the future, Meitaibao and Dr. Du entered into a non-competition undertaking in favor of Henan Genuine and its subsidiaries in April 2020, pursuant to which each of Meitaibao and Dr. Du undertakes not to, among others, (i) directly or indirectly conduct or be involved in any business that directly or indirectly competes, or may compete, with the business engaged by Henan Genuine and its subsidiaries; and (ii) directly or indirectly invest in any company or business that competes directly or indirectly with the business engaged by Henan Genuine and its subsidiaries from time to time.

Based on the arrangements above, our Directors are of the view that there is no competition between our Group and Meitaibao.

Save as disclosed above, as of the Latest Practicable Date, none of our Controlling Shareholders, our Directors and their respective close associates had any interest in any business apart from our business, which competes or is likely to compete, either directly or indirectly with our Company's business which would require disclosure under Rule 8.10 of the Listing Rules.

INDEPENDENCE FROM OUR CONTROLLING SHAREHOLDERS AND THEIR CLOSE ASSOCIATES

We believe that we are capable of carrying on our business independently of our Controlling Shareholders and their respective close associates (other than our Group) after the [**REDACTED**] for the following reasons:

Management Independence

Our Board comprises three executive Directors, two non-executive Directors and three independent non-executive Directors. As of the Latest Practicable Date, save for one of our executive Directors, namely Mr. Wang Lin, who is concurrently serving as the deputy general manager of Xingyu Zhongke, none of our Directors or the members of our senior management team held any position at our Controlling Shareholders or their respective close associates.

Each of our Directors is aware of his/her fiduciary duties as a Director, which require, among other things, that he/she acts for the benefit and in the best interests of our Company and does not allow any conflict between his/her duties as a Director and his/her personal interests. In the event that there is any potential conflict of interest arising out of any transaction to be entered into between our Group and any of the Directors or their respective close associates, the interested Director(s) shall, save in certain circumstances provided by the Articles of Association, abstain from voting at the relevant board meetings of our Company in respect of such transactions and shall not be counted in the quorum.

Based on the reasons above, our Directors are of the view that our Group is capable of managing our business independently from our Controlling Shareholders and/or their respective close associates after the [**REDACTED**].

Operational Independence

We have full rights to make all decisions on, and to carry out, our own business operations independently from our Controlling Shareholders and their respective close associates and will continue to do so after the [**REDACTED**]. Our Group is able to operate without reliance on our Controlling Shareholders and their respective close associates.

Research and Development

We have our own R&D platforms in Shenzhen and Shanghai which are independent from our Controlling Shareholders and their respective close associates. As of December 31, 2025, our R&D platforms had employed 77 members, who were all full-time employees of our Group and did not hold any position in our Controlling Shareholders or their respective close associates. In addition, our Group owns 51 registered patents in the PRC and other countries which are necessary for our R&D and operations. With such independent R&D platforms, an experienced and independent R&D team and self-owned patents, our Group has all the requisite resources to carry on our R&D process independently.

Customers, sales and marketing

During the Track Record Period, we primarily sold azvudine to Fosun Pharmaceutical Industrial in accordance with the Fosun Pharma Agreements after azvudine was approved for marketing in China. Considering the evolving market conditions and in the best interest of both parties, we entered into the Amendment Agreement with Fosun Pharmaceutical Industrial in September 2024, regaining the commercialization right under the Fosun Pharma Agreements. See "—Our Technology Transfer Arrangements and Collaborations—Fosun Pharma Strategic Cooperation Agreement" for details.

As of December 31, 2025, we had entered into distribution agreements with 81 offline distributors and ten online distributors and we do not expect to sell our products through our Controlling Shareholders and/or their respective close associates.

Suppliers/procurement

We procure parts and materials used in R&D independently. We have independent access to our suppliers as well as business partners independent of our Controlling Shareholders and their respective close associates.

Operational facilities and administration

As of the Latest Practicable Date, we had leased premises in Henan from Pingdingshan Xingyu, a company indirectly owned as to 80% by Mr. Wang, with a total GFA of approximately 22,262 sq.m. from January 1, 2019 to December 31, 2038 on terms which are comparable to market terms and other independent transactions, for our operations. Save as disclosed above, all the properties, facilities and equipment necessary to our business operations are independent from our Controlling Shareholders and their respective close associates.

In addition, we have a full-time management team and staff to carry out our own administration and operation independently from our Controlling Shareholders and their respective close associates. All key administrative functions have been and will be carried out by our own without reliance or the support of our Controlling Shareholders and their respective close associates.

Employees

As of the Latest Practicable Date, all of our full-time employees were recruited independently from our Controlling Shareholders and their respective close associates and primarily through both internal referrals and external sources such as recruiting websites and third-party recruiters.

Financial Independence

As of the Latest Practicable Date, all loans, advances and balances due to or from our Controlling Shareholders or their close associates which were not arising out of the ordinary course of business had been fully settled, and all guarantees provided by our Controlling Shareholders and their respective close associates on the borrowings of our Group had been fully released and vice versa.

In addition, we have our own internal control and accounting systems, accounting and finance department, independent treasury function for cash receipts and payment and independent access to third party financing. Accordingly, we believe we are able to maintain financial independence from our Controlling Shareholders and their respective close associates.

CORPORATE GOVERNANCE MEASURES

Each of our Controlling Shareholders has confirmed that he/it fully comprehends his/its obligations to act in our Shareholders' best interests as a whole and is fully aware of the compliance of Rule 8.10 of the Listing Rules. Our Directors believe that there are adequate corporate governance measures in place to manage existing or potential conflicts of interest. In particular, in order to further avoid potential conflicts of interest, we have implemented the following measures:

(i) as part of our preparation for the [**REDACTED**], we [have conditionally adopted] our Articles of Association to comply with the Listing Rules. In particular, our Articles of Association provided that, unless otherwise provided, a Director shall not vote on any resolution approving any contract or arrangement or any other proposal in which such Director or any of his/her close associates have a material interest nor shall such Director be counted in the quorum present at the meeting;

(ii) a Director with material interests shall make full disclosure in respect of matters that may have conflict or potentially conflict with any of our interest and abstain from the board meetings on matters in which such Director or his/her associates have a material interest, unless the attendance or participation of such Director at such meeting of the Board is specifically requested by a majority of the independent non-executive Directors;

(iii) we are committed that our Board should include a balanced composition of executive Directors, non-executive Directors and independent non-executive Directors. We [have appointed] three independent non-executive Directors and we believe our independent non-executive Directors possess sufficient experience and they are free from any business or other relationship which could interfere in any material manner with the exercise of their independent judgment and will be able to provide an impartial and external opinion to protect the interests of our public Shareholders. Details of our independent non-executive Directors are set out in "Directors and Senior Management—Board of Directors—Independent non-executive Directors" in this document;

(iv) we have appointed Guotai Junan Capital Limited as our compliance advisor, which will provide advice and guidance to us in respect of compliance with the applicable laws and the Listing Rules including various requirements relating to Directors' duties and corporate governance; and

(v) as required by the Listing Rules, our independent non-executive Directors shall review any continuing connected transactions annually and confirm in our annual report that such transactions have been entered into in our ordinary and usual course of business, are either on normal commercial terms or on terms no less favorable to us than those available to or from independent third parties and on terms that are fair and reasonable and in the interests of our Shareholders as a whole.